Prometheus Biosciences Inc (Prometheus Biosciences) is a biotech company that discovers, develops and commercializes novel therapeutic and companion diagnostic product candidates for inflammatory bowel disease (IBD).
The company’s pipeline products include PRA023, an anti-TL1A mAb for the treatment of ulcerative colitis and crohn’s disease; and PR600, PR300, PR1100, PR1800 and PR2100 against inflammatory bowel disease (IBD). It utilizes Prometheus360, a medicine platform that combines machine learning-based analytical process to develop its products.
Prometheus Biosciences is also investigating therapeutics for gastrointestinal (GI) diseases targeting other autoimmune diseases. Prometheus Biosciences is headquartered in San Diego, California, the US.